Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04237584
Previous Study | Return to List | Next Study

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04237584
Recruitment Status : Recruiting
First Posted : January 23, 2020
Last Update Posted : July 17, 2020
Sponsor:
Collaborators:
Bayer
Carolina Urologic Research Center
Tulane University
Barbara Ann Karmanos Cancer Institute
Information provided by (Responsible Party):
MANA RBM

Brief Summary:
This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.

Condition or disease Intervention/treatment Phase
Metastatic Castration-resistant Prostate Cancer Drug: Darolutamide Drug: Enzalutamide Drug: Radium-223 Other: Placebo Phase 3

Detailed Description:
The hypothesis investigators will test in this study is whether layering radium-223 following 16 weeks of enzalutamide or darolutamide exposure in patients demonstrating a biochemical response improves disease outcomes. By adding radium-223 following a potential bone flare phenomenon [after first 12-14 weeks of therapy with an androgen receptor blocker (ARB)], including patients expected to have durable response to systemic therapy, and mandating the use of bone protective agents during treatment, the investigators aim to demonstrate an optimal time to add radium-223 in the mCRPC landscape.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 499 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Lead-in open-label androgen-receptor blocker (ARB) followed by double-blind Radium-223 or placebo.
Masking: Double (Participant, Investigator)
Masking Description: Masking of Radium-223 or placebo only
Primary Purpose: Treatment
Official Title: ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients
Actual Study Start Date : June 30, 2020
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : September 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Lead-in ARB followed by Radium-223/ARB
Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Radium-223 + ARB.
Drug: Darolutamide
Participants will be randomly assigned to 12 weeks lead-in ARB (darolutamide or enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Other Name: Nubeqa

Drug: Enzalutamide
Participants will be randomly assigned to 12 weeks lead-in ARB (darolutamide or enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Other Name: Xtandi

Drug: Radium-223
After a 12-week lead-in period of open-label ARB, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label ARB.
Other Name: Xofigo

Placebo Comparator: Lead-in ARB followed by Placebo/ARB
Randomized, Open-label Lead-in ARB (Enzalutamide or Darolutamide) followed by Placebo + ARB.
Drug: Darolutamide
Participants will be randomly assigned to 12 weeks lead-in ARB (darolutamide or enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Other Name: Nubeqa

Drug: Enzalutamide
Participants will be randomly assigned to 12 weeks lead-in ARB (darolutamide or enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Other Name: Xtandi

Other: Placebo
After a 12-week lead-in period of open-label ARB, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label ARB.
Other Name: Saline solution




Primary Outcome Measures :
  1. Symptomatic skeletal event-free survival (SSE-FS) [ Time Frame: through study completion, an average of 5 years ]

    SSE-FS is a composite endpoint, composed of 4 events that indicate disease progression:

    • the first use of external-beam radiation therapy to relieve skeletal tumor-related symptoms
    • the occurrence of new symptomatic pathologic bone fractures.
    • the occurrence of new symptomatic spinal cord compression
    • a tumor-related orthopedic surgical intervention


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: through study completion, an average of 5 years ]
  2. Time to chemotherapy initiation [ Time Frame: through study completion, an average of 5 years ]
  3. Radiographic progression-free survival (rPFS) [ Time Frame: through study completion, an average of 5 years ]
  4. Safety profile of androgen receptor blocker (ARB) therapy with or without radium-223; number of participants with treatment-related adverse events as assessed by CTCAE v5.0. [ Time Frame: through study completion, an average of 5 years ]
  5. Occurrence of AESI: bone fractures (pathologic and non-pathologic) [ Time Frame: through study completion, an average of 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to provide informed consent.
  2. Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.
  3. Men ≥ 18 years.
  4. ECOG performance status of 0 or 1 at screening.
  5. Metastatic to bone with ≥ 2 bone metastases (area of increased uptake on 99mTc bone scan); equivocal lesions on the bone scan must be confirmed by standard X-ray, CT, or MRI.
  6. Patients must have progressive metastatic castration-resistant prostate cancer (mCRPC) at screening and on androgen deprivation therapy (ADT) as evidenced by either:

    1. For patients who manifest disease progression solely as a rising prostate-specific antigen (PSA) level - documentation of a sequence of two rising PSA values at a minimum of 1-week apart with the Screening value ≥1 ng/ml (see Appendix D);
    2. For patients with disease progression manifested in the bone, irrespective of progression by rising PSA - defined by the appearance of 2 or more new skeletal lesions demonstrated by 99Tc bone imaging. Ambiguous results should be confirmed by other imaging modalities than bone scan and x-ray (e.g.: CT-scan or MRI).
    3. For patients with disease progression manifested at nodal sites, irrespective of progression by rising PSA - progression defined per RECIST 1.1.
  7. Ongoing ADT with luteinizing hormone-releasing hormone (LHRH) agonist or antagonist or bilateral orchiectomy.
  8. Use of bone health agents (denosumab or zoledronic acid or other bisphosphonates) starting any time prior to R1 unless contraindicated or considered not in the best interest of the patient. A waiver must be approved by the medical monitor if bone health agents cannot be used. Bone health agents should be continued throughout both RT1 and RT2 treatment periods.
  9. Adequate bone marrow and organ function as defined by:

    1. Hemoglobin ≥ 10.0 g/dL
    2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    3. Platelets ≥ 100 x 109/L
    4. Serum creatinine ≤ 1.95 mg/dL
    5. Estimated creatinine clearance >/= 30 mL/min by Cockroft-Gault calculation
    6. Alanine aminotransferase (ALT) ≤ 175 U/L
    7. Aspartate aminotransferase (AST) ≤ 100 U/L
    8. Total bilirubin ≤ 1.8 mg/dL (unless the patient a diagnosis of Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin; in patients with Gilbert's, the total bilirubin should be less than 6 mg/dL if patient has Gilbert's and the elevation should be seen in the unconjugated or indirect bilirubin measurement)
    9. LDH ≤ 224 U/L at screening.
    10. Albumin ≥ 2.5 g/dL
  10. Fertile male patients, defined as all males physiologically capable of conceiving offspring with female partners of child-bearing potential, must be willing to use condoms plus spermicidal agent during the study treatment period and for 6 months after the last dose of study drug, and not father a child or donate sperm during this period.
  11. The treating site investigator deems RT1 (Enzalutamide or Darolutamide) treatment safe and feasible.

    Subjects must meet the remaining inclusion criteria in order to be qualified for the second randomization (R2). Only subjects that complete the initial 12 weeks of run-in RT1 should be evaluated. Prior inclusion criteria do not need to be re-evaluated:

  12. Patients must have a documented ≥ 30% decline of PSA at any time during the 12 weeks of RT1.
  13. Patients must have no evidence of visceral metastatic disease at the time of RT2 randomization
  14. Ongoing treatment with RT1 and bone health agents at time of RT2 randomization.
  15. The treating site investigator deems RT2 (Ra-223 dichloride) treatment safe and feasible.

Exclusion Criteria:

  1. Pathological finding consistent with small cell carcinoma of the prostate.
  2. Prior chemotherapy for CRPC. Prior docetaxel for hormone-sensitive disease is permitted under the following conditions: started within 3 months of ADT initiation, given for a maximum of 6 cycles and progression occurred > 6 months after the last dose of docetaxel.
  3. Prior treatment for mCRPC or CRPC. However, the following therapies are permitted and not exclusionary: Sipuleucel-T, 5-alpha-reductase inhibitors, estrogens, or older antiandrogens (such as flutamide, bicalutamide, or nilutamide).
  4. Prior treatment for more than 2 months with CYP17 inhibitors (e.g. abiraterone or orteronel).
  5. Prior treatment for more than 2 months with agents inhibiting androgen receptor signaling (e.g. enzalutamide, apalutamide, or darolutamide).
  6. Prior hemibody or whole-body external radiotherapy. Other types of prior external radiotherapy and brachytherapies are allowed.
  7. Prior therapy with radionuclides (e.g., radium-223, strontium-89, samarium-153, rhenium-186, rhenium-188, actinium-225 and lutetium-177).
  8. Current involvement in any drug or device trial involving investigational agent or medical device within the last 28 days prior to R1.
  9. In general, any prior investigational agent for nmCRPC/mCRPC; however, may be reviewed by medical monitor/PIs for waiver consideration, on a case-by-case basis.
  10. Hypersensitivity to compounds related to enzalutamide, darolutamide, or Ra-223.
  11. A blood transfusion ≤ 28 days prior to R1.
  12. Major surgical procedures ≤ 28 days or minor surgical procedures ≤7 days prior to R1. No waiting period is required following port-a-cath placement.
  13. Patients with visceral metastases, clinical evidence of central nervous system metastases, or leptomeningeal tumor spread as demonstrated via CT/MRI of chest, abdomen, pelvis, and CNS (if needed). CT/MRI of the CNS only performed if suspicion of CNS metastases or leptomeningeal tumor spread. Nodules < 1 cm alone will not be considered visceral metastases. Renal masses < 3 cm will not be considered exclusionary.
  14. Serious active infection at the time of screening or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  15. Presence of other active cancers, or history of treatment for invasive cancer ≤2 years of R1. Patients with Stage I/II cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) and superficial bladder cancer are eligible, as are patients with history of non-melanoma skin cancer.
  16. Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results."

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04237584


Contacts
Layout table for location contacts
Contact: Penelope K Manasco, MD (919) 556-9456 pmanasco@manarbm.com
Contact: Study Help Desk (855) 704-0476 Help@manarbm.com

Locations
Layout table for location information
United States, South Carolina
Research Site Recruiting
Myrtle Beach, South Carolina, United States, 29572
Sponsors and Collaborators
MANA RBM
Bayer
Carolina Urologic Research Center
Tulane University
Barbara Ann Karmanos Cancer Institute
Investigators
Layout table for investigator information
Study Chair: Neal Shore, MD Carolina Urologic Research Center
Layout table for additonal information
Responsible Party: MANA RBM
ClinicalTrials.gov Identifier: NCT04237584    
Other Study ID Numbers: PC18-1005
First Posted: January 23, 2020    Key Record Dates
Last Update Posted: July 17, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MANA RBM:
mCRPC
ARB
Radiopharmaceutical
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases